199 related articles for article (PubMed ID: 9399015)
1. Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy.
Schoenen J; Sawyer J
Cephalalgia; 1997 Oct; 17 Suppl 18():28-40. PubMed ID: 9399015
[TBL] [Abstract][Full Text] [Related]
2. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group.
Headache; 1998 Mar; 38(3):173-83. PubMed ID: 9563207
[TBL] [Abstract][Full Text] [Related]
3. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine.
Martin GR
Cephalalgia; 1997 Oct; 17 Suppl 18():4-14. PubMed ID: 9399012
[TBL] [Abstract][Full Text] [Related]
4. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan.
Edmeads JG; Millson DS
Cephalalgia; 1997 Oct; 17 Suppl 18():41-52. PubMed ID: 9399016
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group.
Rapoport AM; Ramadan NM; Adelman JU; Mathew NT; Elkind AH; Kudrow DB; Earl NL
Neurology; 1997 Nov; 49(5):1210-8. PubMed ID: 9371896
[TBL] [Abstract][Full Text] [Related]
6. Clinical applications of zolmitriptan (Zomig, 311C90).
Lipton RB; Stewart WF
Cephalalgia; 1997 Oct; 17 Suppl 18():53-9. PubMed ID: 9399017
[TBL] [Abstract][Full Text] [Related]
7. 311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. International 311C90 Long-Term Study Group.
Zagami AS
Neurology; 1997 Mar; 48(3 Suppl 3):S25-8. PubMed ID: 9071267
[TBL] [Abstract][Full Text] [Related]
8. Zolmitriptan: a review of its use in migraine.
Spencer CM; Gunasekara NS; Hills C
Drugs; 1999 Aug; 58(2):347-74. PubMed ID: 10473025
[TBL] [Abstract][Full Text] [Related]
9. 311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists.
Ferrari MD
Neurology; 1997 Mar; 48(3 Suppl 3):S21-4. PubMed ID: 9071266
[TBL] [Abstract][Full Text] [Related]
10. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90).
Rolan P
Cephalalgia; 1997 Oct; 17 Suppl 18():21-7. PubMed ID: 9399014
[TBL] [Abstract][Full Text] [Related]
11. [Clinical efficacy of zolmitriptan in migraine].
Leira R; Noya M
Neurologia; 1998 Oct; 13 Suppl 2():16-24. PubMed ID: 9859691
[TBL] [Abstract][Full Text] [Related]
12. Zolmitriptan.
Can Fam Physician; 1999 Jun; 45():1491-4, 1497-501. PubMed ID: 10386213
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design.
Geraud G; Olesen J; Pfaffenrath V; Tfelt-Hansen P; Zupping R; Diener HC; Sweet R
Cephalalgia; 2000 Feb; 20(1):30-8. PubMed ID: 10817444
[TBL] [Abstract][Full Text] [Related]
14. Review of zolmitriptan and its clinical applications in migraine.
Dowson AJ; Charlesworth B
Expert Opin Pharmacother; 2002 Jul; 3(7):993-1005. PubMed ID: 12083998
[TBL] [Abstract][Full Text] [Related]
15. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine.
Gallagher RM; Dennish G; Spierings EL; Chitra R
Headache; 2000 Feb; 40(2):119-28. PubMed ID: 10759911
[TBL] [Abstract][Full Text] [Related]
16. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period.
Thomsen LL; Dixon R; Lassen LH; Gibbens M; Langemark M; Bendtsen L; Daugaard D; Olesen J
Cephalalgia; 1996 Jun; 16(4):270-5. PubMed ID: 8792040
[TBL] [Abstract][Full Text] [Related]
17. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig).
Proietti-Cecchini A; Afra J; Schoenen J
Cephalalgia; 1997 Dec; 17(8):849-54; discussion 799. PubMed ID: 9453273
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group.
Solomon GD; Cady RK; Klapper JA; Earl NL; Saper JR; Ramadan NM
Neurology; 1997 Nov; 49(5):1219-25. PubMed ID: 9371897
[TBL] [Abstract][Full Text] [Related]
19. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study.
Dodick D; Brandes J; Elkind A; Mathew N; Rodichok L
CNS Drugs; 2005; 19(2):125-36. PubMed ID: 15697326
[TBL] [Abstract][Full Text] [Related]
20. Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache.
Mauskop A; Farkkila M; Hering-Hanit R; Rapoport A; Warner J
Curr Med Res Opin; 1999; 15(4):282-9. PubMed ID: 10640260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
